Annals of Neurology

Papers
(The H4-Index of Annals of Neurology is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
215
Reply to “Urinary α‐Synuclein for Parkinson's Detection: Key Limitations and Future Directions”184
Issue Information159
133
Vertebral Artery Pseudoaneurysm: Novel Marker of Bow Hunter's Syndrome121
HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis119
103
Annals of Neurology: Volume 97, Number 1, January 202599
Cortical Microhemorrhage Presentation of Small Vessel Primary Angiitis of the Central Nervous System97
Septin‐5 and ‐7‐IgGs: Neurologic, Serologic, and Pathophysiologic Characteristics97
Network Localization of Awareness in Visual and Motor Anosognosia90
Blood Pressure after Successful Endovascular Therapy: A Systematic Review and Meta‐Analysis of Randomized Control Trials87
Microneurography Reveals Unmyelinated Small Nerve Fiber Dysfunction in Long COVID82
Carotid Stent Fracture82
Staufen Impairs Autophagy in Neurodegeneration81
Effect of Imaging Markers on Reperfusion Therapy in Basilar Artery Occlusion79
Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein–Barr Virus in MS Development: A Presymptomatic Case–Control Study78
A Letter Concerning a Role for Blood–Brain Barrier Dysfunction in Delirium following Noncardiac Surgery in Older Adults78
Furthering Female Faculty: An American Neurological Association/Association of University Professors of Neurology Perspective78
Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids: A Potentially Overlooked Diagnosis77
Guanylate Kinase 1 Deficiency: A Novel and Potentially Treatable Mitochondrial DNA Depletion/Deletions Disease74
The Use of Antihypertensive Medication and In Vivo Alzheimer's Disease Pathology74
Association of Retromer Deficiency and Tau Pathology in Down Syndrome71
Probabilistic Mapping Reveals Optimal Stimulation Site in Essential Tremor70
Dysregulation of Gut Microbiota‐Derived Neuromodulatory Amino Acid Metabolism in Human Immunodeficiency Virus‐Associated Neurocognitive Disorder: An Integrative Metagenomic and Metabolomic 64
Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis61
MS ‐Driven Metabolic Alterations Are Recapitulated in iPSC ‐Derived Astrocytes60
Cerebrospinal Fluid Flow in Patients with Huntington's Disease59
Frailty across Neurological Diseases: Why Sex and Gender Matter59
Efficacy and Safety of Ofatumumab Treatment for Anti‐NMDA Receptor Autoimmune Encephalitis (OFF‐AE): A Prospective, Multicenter Cohort Study57
Before, during, and after: An Argument for Safety and Improved Outcome of Thrombolysis in Acute Ischemic Stroke with Direct Oral Anticoagulant Treatment56
Plasma Metabolites Link Dietary Patterns to Stroke Risk56
Elevated Cerebrospinal Fluid Ubiquitin Carboxyl‐Terminal Hydrolase Isozyme L1 in Asymptomatic C9orf72 Hexanucleotide Repeat Expansion Carriers56
Diet, Pace of Biological Aging, and Risk of Dementia in the Framingham Heart Study55
Prevalence of Cerebral Amyloid Angiopathy and Associated Risk of Subsequent Ischemic and Hemorrhagic Stroke and Mortality in a Nationwide Cohort55
Biological Age Acceleration and Motoric Cognitive Risk Syndrome55
A Managed Care System with Telemedicine Support for Neurological Emergencies54
Management of Cerebral Venous Thrombosis Due to Adenoviral COVID‐19 Vaccination52
A Role for Insulin‐like Growth Factor 1 in the Generation of Epileptic Spasms in a murine model50
Cover Image48
Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS48
Severity of GNAO1‐Related Disorder Correlates with Changes in G‐Protein Function48
Issue Information47
Annals of Neurology: Volume 94, Number S30, September 202347
Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease47
Longitudinal Imaging Biomarkers Correlate with Progressive Motor Deficit in the Mouse Model of Charlevoix‐Saguenay Ataxia46
0.0850510597229